A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in OCD (OCD) patients resistant to Selective Seroton...
This historical record does not confirm current site availability.
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with OCD. Other eligibility criteria apply.
- Listed locations
- Bulgaria · Czechia and 2 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This is historical registry information. What is the current study status and protocol?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 120
- Sponsor
- Novartis Pharma Services AG
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Bulgaria, Czechia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2012-005000-17
- Official title
Show the full official title
A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...
Recruitment & locations
Bulgaria · Czechia · Germany
1 more locations
- United Kingdom
Registry details
- Bulgaria — Prematurely Ended
- Czechia — Prematurely Ended
- Germany — Prematurely Ended
- United Kingdom — Prematurely Ended
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharma Services AG, a pharmaceutical company.
Who can participate?
This study is for people with OCD. Other eligibility criteria apply.
Is this study still recruiting?
The historical registry lists this study as terminated.
